As of January 20, 2026, the global financial landscape is grappling with a sudden and aggressive escalation in trade tensions, as the U.S. administration pivots from traditional protectionism to a geopolitical showdown over Arctic territory. President Trump has intensified his long-standing ambition to acquire Greenland, issuing a direct ultimatum
The morning of January 20, 2026, 3M (NYSE: MMM) released its fourth-quarter and full-year 2025 financial results, signaling a definitive turn in the company’s multi-year effort to shed its image as a litigation-burdened conglomerate and re-emerge as a lean industrial powerhouse. The company reported adjusted earnings per share (EPS)
Industrial conglomerate 3M (NYSE:MMM) announced better-than-expected revenue in Q4 CY2025, with sales up 5.6% year on year to $6.13 billion. Its non-GAAP profit of $1.83 per share was 1.7% above analysts’ consensus estimates.
Earnings season ramps up this week with some big names set to report. This week we have Netflix, Intel, Johnson & Johnson, Freeport McMoran and 3M Company all reporting in what shapes as a busy and pivotal week for stocks.
Date: January 19, 2026 Author: Finterra Research Team Introduction As the opening bell prepares to ring on a new week, all eyes in the industrial sector are fixed on St. Paul. 3M Company (NYSE: MMM), once the poster child for "litigation-induced value traps," has undergone a metamorphosis over the last 24 months. Today, on the [...]
As the world’s financial elite gather for the annual World Economic Forum in Davos, a stark divergence has emerged in the global executive psyche. While much of the world is cautiously eyeing a recovery from years of inflationary pressure, a flurry of mid-January 2026 surveys reveals that United States
Date: January 14, 2026 Introduction Since its high-profile separation from industrial conglomerate 3M Company (NYSE: MMM) in April 2024, Solventum Corporation (NYSE: SOLV) has undergone a profound transformation. Once a steady but overshadowed healthcare division, Solventum has emerged as a focused, multi-billion-dollar medtech powerhouse. As of early 2026, the company is in the spotlight for [...]
